Date Field | Doc. No. | Party | Description |
---|
Aug 10, 2016 | 1007 | | Tannock 2004 Download |
Aug 10, 2016 | 1009 | | Harrison's Principles of Internal Medicine 2005 Download |
Aug 10, 2016 | 1051 | | Kirby 2011 Download |
Aug 10, 2016 | 1027 | | Miller 1954 Download |
Aug 10, 2016 | 1060 | | Cowen & Company- J&J Download |
Aug 10, 2016 | 1043 | | Fisher 1993 Download |
Aug 10, 2016 | 1054 | | Mayo Clinic- Hormone Therapy Download |
Aug 10, 2016 | 1064 | | FDA News Release- June 17, 2010 Download |
Aug 10, 2016 | 1062 | | Zytiga Brochure Download |
Aug 10, 2016 | 1021 | | Ryan 2011 Download |
Aug 10, 2016 | 1032 | | The Pharmacological Basis of Therapeutics 1990 Download |
Aug 10, 2016 | 1028 | | Tannock 1989 Download |
Aug 10, 2016 | 1068 | | Wedbush- July 14, 2015 Download |
Aug 10, 2016 | 1016 | | Scholz 2005 Download |
Aug 10, 2016 | 1029 | | Scher 2005 Download |
Aug 10, 2016 | 1035 | | Potter 1995 Download |
Aug 10, 2016 | 1006 | | Sartor 1998 Download |
Aug 10, 2016 | 1044 | | Bearden 1977 Download |
Aug 10, 2016 | 1023 | | Ryan 2013 Download |
Aug 10, 2016 | 1004 | | Gerber 1990 Download |
Aug 10, 2016 | 1061 | | William Blair- Jan. 22, 2013 Download |
Aug 10, 2016 | 1041 | | Remington's Pharmaceutical Sciences 1980 Download |
Aug 10, 2016 | 1019 | | Berry 2002 Download |
Aug 10, 2016 | 1047 | | Yamamoto 1994 Download |
Aug 10, 2016 | 1013 | | Trump 1989 Download |
Aug 10, 2016 | 1039 | | Santen 1983 Download |
Aug 10, 2016 | 1067 | | UBS Research- Feb. 3, 2014 Download |
Aug 10, 2016 | 1052 | | Zytiga Label Download |
Aug 10, 2016 | 1069 | | Barron's- RBC Capital Markets Download |
Aug 10, 2016 | 1049 | | American Cancer Society Download |
Aug 10, 2016 | 1040 | | Sonino 1987 Download |
Aug 10, 2016 | 1033 | | Review of Medical Physiology 1979 Download |
Aug 10, 2016 | 1065 | | Nasdaq- Aug. 5, 2014 Download |
Aug 10, 2016 | 1034 | | Taxotere Prescribing Information 2004 Download |
Aug 10, 2016 | 1012 | | Hellerstedt 2002 Download |
Aug 10, 2016 | 1059 | | Patent Valuation: Improving Decision Making through Analysis 2012 Download |
Aug 10, 2016 | 1031 | | File History of USPN 8,822,438 Download |
Aug 10, 2016 | 1058 | | Zytiga Orange Book Download |
Aug 10, 2016 | 1038 | | Rajfer 1986 Download |
Aug 10, 2016 | 1063 | | Jevtana Website Download |
Aug 10, 2016 | 1037 | | MacAdams 1986 Download |
Aug 10, 2016 | 1010 | | Tannock 1996 Download |
Aug 10, 2016 | 1070 | | Cowen & Company- July 2, 2012 Download |
Aug 10, 2016 | 1018 | | Brassell 2005 Download |
Aug 10, 2016 | 1020 | | FDA Press Release- May 19, 2004 Download |
Aug 10, 2016 | 1042 | | Sartor 2011 Download |
Aug 10, 2016 | 1048 | | Mayo Clinic- Prostate Cancer Download |
Aug 10, 2016 | 1001 | | USPN 8,822,438 Download |
Aug 10, 2016 | 1 | | Power of Attorney Download |
Aug 10, 2016 | 1024 | | Danila 2010 Download |
Aug 10, 2016 | 1050 | | ASCO- Sept. 8, 2014 Download |
Aug 10, 2016 | 1055 | | Drugs @ FDA Download |
Aug 10, 2016 | 1026 | | Small 2001 Download |
Aug 10, 2016 | 1053 | | Zytiga Website Download |
Aug 10, 2016 | 1011 | | Harris 2002 Download |
Aug 10, 2016 | 1045 | | Mauro 2003 Download |
Aug 10, 2016 | 1046 | | Scher 2004 Download |
Aug 10, 2016 | 1022 | | Attard 2009 Download |
Aug 10, 2016 | 1014 | | Costa-Santos 2004 Download |
Aug 10, 2016 | 1017 | | Fossa 2001 Download |
Aug 10, 2016 | 1066 | | Medivation Press Release- Sept. 10, 2014 Download |
Aug 10, 2016 | 1056 | | FDA News Release- Dec. 10, 2012 Download |
Aug 10, 2016 | 1030 | | USPN 5,604,213 Download |
Aug 10, 2016 | 1025 | | Kelly 1993 Download |
Aug 10, 2016 | 1003 | | Paul A. Godley Curriculum Vitae Download |
Aug 10, 2016 | 1057 | | Wells Fargo Securities- J&J Download |
Aug 10, 2016 | 1008 | | Attard 2005 Download |
Aug 10, 2016 | 1005 | | O'Donnell 2004 Download |
Aug 10, 2016 | 1015 | | Oh 2002 Download |
Aug 10, 2016 | 1036 | | Fakih 2002 Download |
Aug 10, 2016 | 1073 | | William Blair- July 14, 2015 Download |
Aug 10, 2016 | 1074 | | Bloomberg.com- Apr. 6, 2016 Download |
Aug 10, 2016 | 1078 | | Robert D. Stoner Curriculum Vitae Download |
Aug 10, 2016 | 1072 | | UBS Zytiga Label Extended Download |
Aug 10, 2016 | 1071 | | Credit Suisse- Dec. 11, 2012 Download |
Aug 10, 2016 | 1075 | | Industrial Market Structure and Economic Performance 1990 Download |
Aug 10, 2016 | 1080 | | IMS Data- 2012-2015 Download |
Aug 10, 2016 | 1079 | | Attard 2008 Download |
Aug 10, 2016 | 1076 | | hurdle rate definition Download |
Aug 10, 2016 | 2 | | Paul A. Godley, M.D., Ph.D., MPP Dec Download |
Aug 10, 2016 | 4 | | Petition Download |
Aug 10, 2016 | 3 | | Robert D. Stoner, Ph.D. Dec Download |
Aug 16, 2016 | 1002 | | Declaration of Paul A. Godley, M.D., Ph.D., MPP Download |
Aug 16, 2016 | 1077 | | Declaration of Robert D. Stoner, Ph.D. Download |
Aug 16, 2016 | 6 | | Notice of Corrected Petition Download |
Aug 16, 2016 | 5 | | Notice of Filing Date Accorded to Petition Download |
Aug 17, 2016 | 7 | | Notice of Accepting Corrected Petition Download |
Aug 25, 2016 | 10 | | Janssen Oncology, Inc.s Exhibit List Download |
Aug 25, 2016 | 2001 | | Janssen Oncology, Incs Exhibit List Download |
Aug 25, 2016 | 8 | | Janssen Oncology, Incs Mandatory Notices Download |
Aug 25, 2016 | 9 | | Janssen Oncology, Incs Power of Attorney Download |
Nov 16, 2016 | 13 | | Janssen Oncology Incs Preliminary Response Download |
Nov 16, 2016 | 2005 | | Public Version of 6/6/2016 ¿¿¿ 7/23/2016 Email Chain between J. Reda and V. Dhanorkar Download |
Nov 16, 2016 | 11 | | Motion to Seal Download |
Nov 16, 2016 | 14 | | Janssen Oncology Incs Exhibit List Download |
Nov 16, 2016 | 2004 | | Public Version of Declaration of Jennifer Reda Download |
Nov 16, 2016 | 2006 | | Standing Protective Order Download |
Nov 16, 2016 | 2007 | | Redline of Standing Protective Order Download |
Nov 28, 2016 | 15 | | Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of David T. Pritikin Download |
Nov 28, 2016 | 16 | | Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Bindu Donovan Download |
Nov 28, 2016 | 2009 | | Declaration of Bindu Donovan in Support of Motion to Appear Pro Hac Vice Download |
Nov 28, 2016 | 2008 | | Declaration of David T. Pritikin in Support of Motion to Appear Pro Hac Vice Download |
Dec 5, 2016 | 17 | | Order Authorizing Reply and Surreply to Patent Owner Preliminary Response Download |
Dec 5, 2016 | 18 | | Decision - Motion for Pro Hac Vice Admission (Pritikin) Download |
Dec 5, 2016 | 19 | | Decision - Motion for Pro Hac Vice Admission (Donovan) Download |
Dec 9, 2016 | 21 | | BTG International Limiteds Power of Attorney Download |
Dec 9, 2016 | 20 | | Patent Owners Updated Mandatory Notices Download |
Dec 13, 2016 | 1081 | | Declaration of Gopal Venkatesan Download |
Dec 13, 2016 | 22 | | Petitioner's Reply to Patent Owner Preliminary Response Download |
Dec 19, 2016 | 2010 | | 2016/11/10 (DI 239)-Opinion on Markman Patent Claim Construction (DNJ) Download |
Dec 19, 2016 | 2011 | | 2016/14/10 (DI 240)-Order on Markman Patent Claim Construction (DNJ) Download |
Dec 19, 2016 | 23 | | Janssen Oncology, Inc.s Exhibit List Download |
Dec 19, 2016 | 24 | | Order Conduct of the Proceeding Download |
Dec 22, 2016 | 25 | | Motion to Seal Download |
Dec 22, 2016 | 27 | | Janssen Oncology Inc.s Surreply to Patent Owner Preliminary Response Download |
Jan 19, 2017 | 29 | | Decision - Institution of Inter Partes Review - 37 C.F.R. 42.108 Download |
Jan 19, 2017 | 30 | | Scheduling Order Download |
Jan 27, 2017 | 32 | | Janssen Oncology, Inc.s Updated Mandatory Notices Download |
Jan 27, 2017 | 31 | | Patent Owners Notice of Designation of Additional Backup Counsel Download |
Feb 2, 2017 | 33 | | Petitioner's Objections to Patent Owner's Evidence Download |
Feb 2, 2017 | 34 | | Patent Owners Objections to Evidence Pursuant to 37 C.F.R. 42.64(b)(1) Download |
Feb 3, 2017 | 35 | | Patent Owners Notice of Deposition of Robert D. Stoner, Ph.D. Download |
Feb 6, 2017 | 36 | | Notice of Stipulation to Change Due Dates 1 and 2 Download |
Feb 28, 2017 | 37 | | Patent Owners Notice of Deposition of Paul A. Godley, M.D., Ph.D., MPP Download |
Mar 2, 2017 | 38 | | Petitioner's Updated Mandatory Notices Download |
Mar 16, 2017 | 39 | | Petitioner's Notice of Deposition of Richard Auchus, M.D., Ph.D. Download |
Mar 17, 2017 | 2028 | | JSN 2028 Declaration of Professor Ian Judson, M.D. Download |
Mar 17, 2017 | 2070 | | JSN 2070 FDA Press Release (2011) Download |
Mar 17, 2017 | 2084 | | JSN 2084 ImmunoGen, Inc. Form 8-K, Item 8.01 Download |
Mar 17, 2017 | 2019 | | JSN 2019 Declaration of Scott Serels, MD, filed on Jan. 16, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. Download |
Mar 17, 2017 | 2047 | | JSN 2047 Stamey et al., ¿¿¿Prostate-Specific Antigen As A Serum Marker For Adenocarcinoma Of The Prostate,¿¿¿ NEJM, 317(15):909-916 (1987) Download |
Mar 17, 2017 | 2102 | | JSN 2102 Mayo Clinic ¿¿¿ Prednisone and other corticosteroids Download |
Mar 17, 2017 | 2015 | | JSN 2015 Declaration of Dr. Marc Garnick Download |
Mar 17, 2017 | 2088 | | JSN 2088 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 78, 751-764 Download |
Mar 17, 2017 | 2071 | | JSN 2071 Ryan et al., ¿¿¿Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer Download |
Mar 17, 2017 | 2057 | | JSN 2057 Bubley et al., ¿¿¿Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group,¿¿¿ J. Clin. Oncology, 17:3461-3467 (1999) Download |
Mar 17, 2017 | 2080 | | JSN 2080 Antonarakis and Eisenberger, ¿¿¿Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences,¿¿¿ J. Clin. Oncology, 31(14):1709-1712 (2013) Download |
Mar 17, 2017 | 2072 | | JSN 2072 Booth et al., ¿¿¿Oncology¿¿¿s trials,¿¿¿ Nature Reviews, 2:609-610 (2003) Download |
Mar 17, 2017 | 2110 | | JSN 2110 J&J January 22, 2013 Press Release ¿¿¿ Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results Download |
Mar 17, 2017 | 2051 | | JSN 2051 Dorin et al., ¿¿¿Diagnosis of Adrenal Insufficiency,¿¿¿ Ann. Inern. Med., 139:194-204 (2003) Download |
Mar 17, 2017 | 2030 | | JSN 2030 Clinical Cancer Research Peer Review letter to Judson, dated May 12, 2003 Download |
Mar 17, 2017 | 2106 | | JSN 2106 Orange Book ¿¿¿ Xofigo Download |
Mar 17, 2017 | 2067 | | JSN 2067 Palmer, ¿¿¿Managing Hyperkalemia Caused by Inhibitors of the Renin¿¿¿Angiotensin¿¿¿Aldosterone System,¿¿¿ NEJ, 351:585-592 (2004) Download |
Mar 17, 2017 | 2096 | | JSN 2096 Zytiga Usage ¿¿¿ total promotional spend Download |
Mar 17, 2017 | 2089 | | JSN 2089 NCI - SEER Stat Fact Sheets: Prostate Cancer Download |
Mar 17, 2017 | 2020 | | JSN 2020 Deposition Transcript of Scott Serels, M.D., taken by Patent Owner on August 22, 2016 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286 Download |
Mar 17, 2017 | 2087 | | JSN 2087 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 73, 714-719 Download |
Mar 17, 2017 | 2090 | | JSN 2090 Tucker et al., ¿¿¿Reversible Adrenal Insufficiency Induced by Ketoconazole,¿¿¿ JAMA, 253(16):2413-2414 (1985) Download |
Mar 17, 2017 | 2025 | | JSN 2025 Conde and Aronson, ¿¿¿Risk factors for male osteoporosis,¿¿¿ Urologic Oncology, 21:380-383 (2003) Download |
Mar 17, 2017 | 2095 | | JSN 2095 Zytiga Usage ¿¿¿ prednisone information Download |
Mar 17, 2017 | 2073 | | JSN 2073 Tokai July 26, 2016 Press Release Download |
Mar 17, 2017 | 2074 | | JSN 2074 Active/Ipsen April 16, 2015 Press Release Download |
Mar 17, 2017 | 2026 | | JSN 2026 Remington ¿¿¿ The Science and Practice of Pharmacy, 20th ed., pp. 1363-1370 (2000) Download |
Mar 17, 2017 | 2040 | | JSN 2040 Declaration of Richard Auchus, M.D., Ph.D. Download |
Mar 17, 2017 | 2068 | | JSN 2068 Swartz and Dluhy, ¿¿¿Corticosteroids: Clinical Pharmacology and Therapeutic Use,¿¿¿ Drugs, 16:238-255 (1978) Download |
Mar 17, 2017 | 2013 | | JSN 2013 Johnson & Johnson Press Release 1/26/2016 Download |
Mar 17, 2017 | 2049 | | JSN 2049 Blackard, ¿¿¿Letters to the Editor,¿¿¿ Journal of Urology, 146(6):1621-1622 (1991) Download |
Mar 17, 2017 | 2052 | | JSN 2052 Grinspoon and Biller, ¿¿¿Clinical Review 62 Laboratory Assessment of Adrenal Insufficiency,¿¿¿ J. Clin. Endocrinol. And Metabolism, 79(4):923-931 (1994) Download |
Mar 17, 2017 | 2048 | | JSN 2048 Altman et al., ¿¿¿The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration,¿¿¿ Ann. Intern. Med., 134:663-694 (2001) Download |
Mar 17, 2017 | 2086 | | JSN 2086 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 72, 704-714 Download |
Mar 17, 2017 | 2061 | | JSN 2061 Body, ¿¿¿Low-dose prednisone and increased risk of development of bone metastases,¿¿¿ Annals of Oncology, 7:643-645 (1996) Download |
Mar 17, 2017 | 2014 | | JSN 2014 Johnson & Johnson Press Release 1/24/2017 Download |
Mar 17, 2017 | 2016 | | JSN 2016 Deposition Transcript of Marc B. Garnick, M.D., taken by Patent Owner on February 16, 2017 Download |
Mar 17, 2017 | 2036 | | JSN 2036 Hadaschik et al., ¿¿¿Novel targets and approaches in advanced prostate cancer,¿¿¿ Current Opinions Urology, 17:182-187 (2007) Download |
Mar 17, 2017 | 2062 | | JSN 2062 Craft, ¿¿¿Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure,¿¿¿ BUMC Proceedings, 17:217-220 (2004) Download |
Mar 17, 2017 | 2055 | | JSN 2055 Scher et al., ¿¿¿Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease,¿¿¿ J. Clin. Oncology, 15:2928-2838 (1997) Download |
Mar 17, 2017 | 2085 | | JSN 2085 Sephton, et al., ¿¿¿Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival,¿¿¿ Journal of National Cancer Institute, 92(12):994-1000 (2000) Download |
Mar 17, 2017 | 2104 | | JSN 2104 NCI ¿¿¿ Docetaxel Download |
Mar 17, 2017 | 2038 | | JSN 2038 Declaration of Matthew Rettig, M.D. Download |
Mar 17, 2017 | 2108 | | JSN 2108 Orange Book ¿¿¿ Jevtana Download |
Mar 17, 2017 | 2023 | | JSN 2023 Herr and Pfitzenmaier, ¿¿¿Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic
treatment and metastases,¿¿¿ The Lancet, 7:425-430 (2006) Download |
Mar 17, 2017 | 2065 | | JSN 2065 Farwell, et al., ¿¿¿Total Suppression of Cortisol Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic Hormone Syndrome,¿¿¿ American Journal of Medicine, 84:1063-1066 (1988) Download |
Mar 17, 2017 | 2029 | | JSN 2029 Judson CV Download |
Mar 17, 2017 | 2063 | | JSN 2063 Small et al., ¿¿¿Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583),¿¿¿ J. Clin. Oncology, 22(6):1025-1033 (2004) Download |
Mar 17, 2017 | 2066 | | JSN 2066 Mantero et al., ¿¿¿Long-term treatment of mineralocorticoid excess syndromes,¿¿¿ Steroids, 60:81-86 (1995)- Download |
Mar 17, 2017 | 2012 | | JSN 2012 PM Live Top 50 Pharmaceuticals Download |
Mar 17, 2017 | 2077 | | JSN 2077 OncoGenex (April 28, 2014) Press Release Download |
Mar 17, 2017 | 2017 | | JSN 2017 Declaration of Scott Serels, MD, filed on Dec. 4, 2015 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. Download |
Mar 17, 2017 | 2100 | | JSN 2100 CDC ¿¿¿ ¿¿¿Prostate Cancer¿¿¿ Download |
Mar 17, 2017 | 2081 | | JSN 2081 Genentech March 12, 2010 Press Release Download |
Mar 17, 2017 | 2024 | | JSN 2024 Krishnan et al., ¿¿¿A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic
Implications for Androgen-Independent Prostate Cancer,¿¿¿ Endocrinology, 145:1889-1900 (2002) Download |
Mar 17, 2017 | 2064 | | JSN 2064 Millikan, et al., ¿¿¿Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer,¿¿¿ Urologic Oncology, 6:111-115 (2001) Download |
Mar 17, 2017 | 2042 | | JSN 2042 Papatsoris et al., ¿¿¿Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC),¿¿¿ Current Medicinal Chemistry, 12:277-296 (2005) Download |
Mar 17, 2017 | 2039 | | JSN 2039 Rettig CV Download |
Mar 17, 2017 | 2027 | | JSN 2027 Rumohr and Chang, ¿¿¿Current chemotherapeutic approaches for androgen-independent prostate cancer,¿¿¿ Current Opinion in Investigational Drugs, 7(6):529-533 (2006) Download |
Mar 17, 2017 | 2022 | | JSN 2022 Debruyne and Witjes, ¿¿¿Ketoconazole High Dose (H.D.) In The Management Of Metastatic Prostatic Carcinoma,¿¿¿ The Journal of Urology, 135(4, pt.2):203A, Abstract 397 (1986) Download |
Mar 17, 2017 | 2032 | | JSN 2032 Strother et al., ¿¿¿Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?,¿¿¿ European Journal of Cancer, 41:954-964 (2005) Download |
Mar 17, 2017 | 2035 | | JSN 2035 Press Release 1/20/2015 Download |
Mar 17, 2017 | 2078 | | JSN 2078 BMS Sept. 12, 2013 Press Release Download |
Mar 17, 2017 | 2056 | | JSN 2056 Sternberg, ¿¿¿Hormone refractory metastatic prostate cancer,¿¿¿ Annals of Oncology, 3:331-335 (1992) Download |
Mar 17, 2017 | 2021 | | JSN 2021 Boumpas et al., ¿¿¿Glucocorticoid Therapy for Immune-mediated Diseases: Basic and Clinical Correlates,¿¿¿ Ann. Internal Medicine, 119:1198-1208 (1993) Download |
Mar 17, 2017 | 2105 | | JSN 2105 NCI ¿¿¿ Metastatic Cancer Download |
Mar 17, 2017 | 2031 | | JSN 2031 Burgess and Roth, ¿¿¿Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer,¿¿¿ Urol. Clin. N. Am., 33:227-236 (2006) Download |
Mar 17, 2017 | 2054 | | JSN 2054 Kuzel et al., ¿¿¿A Phase II Study of Continuous Infusion 5-Fluorouracil in Advanced Hormone Refractory Prostate Cancer,¿¿¿ Cancer, 72(6):1965-1968 (1993) Download |
Mar 17, 2017 | 2079 | | JSN 2079 Carducci et al., ¿¿¿A Phase 3 Randomized Controlled Trial of the Efficacy and Safety of Atrasentan in Men With Metastatic Hormone-refractory Prostate Cancer,¿¿¿ Cancer, 110(9):1959-1966 (2007) Download |
Mar 17, 2017 | 2046 | | JSN 2046 Therasse et al., ¿¿¿New Guidelines to Evaluate the Response to Treatment in Solid Tumors,¿¿¿ J. Natl Cancer Inst., 92:205-216 (2000) Download |
Mar 17, 2017 | 2075 | | JSN 2075 Takeda June 19, 2014 Press Release Download |
Mar 17, 2017 | 2099 | | JSN 2099 Cancer.Net - September 8, 2014 ¿¿¿Treatment of Metastatic Castration Resistant Prostate Cancer¿¿¿ Download |
Mar 17, 2017 | 2018 | | JSN 2018 Deposition Transcript of Scott R. Serels, taken by Patent Owner on January 21, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. Download |
Mar 17, 2017 | 2076 | | JSN 2076 Michaelson et al., ¿¿¿Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer,¿¿¿ J. Clin. Oncology, 31:1-8 (2013) Download |
Mar 17, 2017 | 2060 | | JSN 2060 Marini et al., ¿¿¿The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer,¿¿¿ Annals of Oncology, 7:245-250 (1996) Download |
Mar 17, 2017 | 2083 | | JSN 2083 Novacea Form 8-K at 1.02 Download |
Mar 17, 2017 | 2069 | | JSN 2069 Seale and Compton, ¿¿¿Side-effects of corticosteroid agents,¿¿¿, Med. J. of Australia, 144(3):139-142 (1986) Download |
Mar 17, 2017 | 2107 | | JSN 2107 Orange Book ¿¿¿ Xtandi Download |
Mar 17, 2017 | 2041 | | JSN 2041 Auchus CV Download |
Mar 17, 2017 | 2111 | | JSN 2111 Duc et al., ¿¿¿In vitro and in vivo models for the evaluation of potent inhibitors of male rat for the 17¿¿-hydroxylase/C17,20-lyase,¿¿¿ Journal of Steroid Biochemistry & Molecular Biology, 84:537-542 (2003). Download |
Mar 17, 2017 | 2034 | | JSN 2034 Press Release 1/21/2014 Download |
Mar 17, 2017 | 2059 | | JSN 2059 Petrylak et al., ¿¿¿Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,¿¿¿ NEJM, 351:1513-1520 (2004) Download |
Mar 17, 2017 | 2098 | | JSN 2098 ACS ¿¿¿ ¿¿¿What is Prostate Cancer? Topics¿¿¿ Download |
Mar 17, 2017 | 2058 | | JSN 2058 Excerpts from Seifter, Concepts in Medical Physiology, Chapter 34, pp. 540-553, Chapter 37, pp. 606-620 (2005) Download |
Mar 17, 2017 | 2045 | | JSN 2045 Vellturo CV Download |
Mar 17, 2017 | 2109 | | JSN 2109 Hotte and Saad, ¿¿¿Current management of castrate-resistant prostate cancer,¿¿¿ Current Oncology, 17(2):S72-S79 (2010) Download |
Mar 17, 2017 | 2101 | | JSN 2101 J&J May 21, 2009 Press Release Download |
Mar 17, 2017 | 2091 | | JSN 2091 What You Need to Know About Prostate Cancer, NIH Publication No. 12-1576 (2012) Download |
Mar 17, 2017 | 2082 | | JSN 2082 Mulcahy, Medscape October 17, 2008 Press Release Download |
Mar 17, 2017 | 2053 | | JSN 2053 Lara and Meyers, ¿¿¿Treatment Options in Androgen-Independent Prostate Cancer,¿¿¿ Cancer Investigation, 17(2):137-144 (1999) Download |
Mar 17, 2017 | 2043 | | JSN 2043 Armstrong and Carducci, ¿¿¿New drugs in prostate cancer,¿¿¿ Current Opinions Urology, 16:138-145 (2006) Download |
Mar 17, 2017 | 2103 | | JSN 2103 Medical Dictionary ¿¿¿ refractory cancer Download |
Mar 17, 2017 | 2050 | | JSN 2050 MedlinePlus, ¿¿¿ACTH stimulation test,¿¿¿ available at https://medlineplus.gov/ency/article/003696.htm, last visited Sept. 30, 2016 Download |
Mar 17, 2017 | 2136 | | JSN 2136 BTG Webpage from WayBack Machine Download |
Mar 17, 2017 | 2140 | | JSN 2140 J&J Q2 2013 Earnings Call Transcript Download |
Mar 17, 2017 | 2146 | | JSN 2146 J&J Q4 2014 Earnings Call Transcript Download |
Mar 17, 2017 | 2139 | | JSN 2139 J&J Q1 2013 Earnings Call Transcript Download |
Mar 17, 2017 | 2113 | | JSN 2113 Public Citizen Press Room Release ¿¿¿ ¿¿¿Antifungal Treatment Should Be Taken Off the Market, Public Citizen Tells FDA,¿¿¿ dated February 24, 2015. Download |
Mar 17, 2017 | 2165 | | JSN 2165 February 11, 2014 Notice of Allowance (from prosecution history of ¿¿¿438 patent) Download |
Mar 17, 2017 | 2141 | | JSN 2141 J&J Q3 2013 Earnings Call Transcript Download |
Mar 17, 2017 | 2158 | | JSN 2158 ECOG Performance Status,¿¿¿ Download |
Mar 17, 2017 | 2163 | | JSN 2163 Sweeney, et al., ¿¿¿Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer,¿¿¿ NEJM, 373:737-746 (2015) Download |
Mar 17, 2017 | 2145 | | JSN 2145 J&J Q3 2014 Earnings Call Transcript Download |
Mar 17, 2017 | 2129 | | JSN 2129 Eplerenone Label Download |
Mar 17, 2017 | 2168 | | JSN 2168 Zytiga Label (2011) Download |
Mar 17, 2017 | 2138 | | JSN 2138 BTG Annual Report, 2004 Download |
Mar 17, 2017 | 2144 | | JSN 2144 J&J Q2 2014 Earnings Call Transcript Download |
Mar 17, 2017 | 2142 | | JSN 2142 J&J Q4 2013 Earnings Call Transcript Download |
Mar 17, 2017 | 2148 | | JSN 2148 J&J Q2 2015 Earnings Call Transcript Download |
Mar 17, 2017 | 40 | | Petitioner's Notice of Deposition of Matthew Rettig, M.D. Download |
Mar 17, 2017 | 43 | | Janssen Oncology Inc.s Patent Owner Response Download |
Mar 17, 2017 | 2147 | | JSN 2147 J&J Q1 2015 Earnings Call Transcript Download |
Mar 17, 2017 | 2159 | | JSN 2159 de Bono, J.S. et al., ¿¿¿Abiraterone and increased survival in metastatic prostate cancer,¿¿¿ New Engl. J. Med., 364:1995¿¿¿2005 (2011) Download |
Mar 17, 2017 | 2155 | | JSN 2155 Butler affidavit and archive notarization Download |
Mar 17, 2017 | 2117 | | JSN 2117 Williams, ¿¿¿Discontinued Drugs in 2008: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 18(11):1581-1594 (2009) Download |
Mar 17, 2017 | 2114 | | JSN 2114 Williams et al., ¿¿¿Objective Responses to Ketoconazole Therapy in Patients with Relapsed Progressive Prostatic Cancer,¿¿¿ British Journal of Urology, 58:45-51 (1986). Download |
Mar 17, 2017 | 2162 | | JSN 2162 Redacted deposition transcript of Paul A. Godley, taken by Patent Owner on March 7, 2017 Download |
Mar 17, 2017 | 2166 | | JSN 2166 June 2, 2014 Notice of Allowance (from prosecution history of
¿¿¿438 patent) Download |
Mar 17, 2017 | 2116 | | JSN 2116 Williams, ¿¿¿Discontinued Drugs in 2007: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 17(12):1791-1816 (2008) Download |
Mar 17, 2017 | 2131 | | JSN 2131 Van den Akker et al., ¿¿¿Differential Inhibition of 17a-Hydroxylase and 17,20-Lyase Activities by Three Novel Missense CYP17
Mutations Identified in Patients with P450c17 Deficiency,¿¿¿ J. Clin. Endocrinol. & Metabolism, 87(12):5714-5721 (2002) Download |
Mar 17, 2017 | 2151 | | JSN 2151 Patent Owner Response in IPR2016-00286 Download |
Mar 17, 2017 | 2153 | | JSN 2153 Declaration of Ivan Hofmann, filed on June 30, 2016 in Mylan Pharmaceuticals Inc. v. Janssen Oncology, Inc., IPR2016-01332 Download |
Mar 17, 2017 | 2137 | | JSN 2137 BTG Annual Report, 2003 Download |
Mar 17, 2017 | 2128 | | JSN 2128 Deposition Transcript of Ivan T. Hofmann, taken by Patent Owner on February 7, 2017 Download |
Mar 17, 2017 | 2156 | | JSN 2156 Sartor, ¿¿¿The Continuing Challenge of Hormone-Refractory Prostate Download |
Mar 17, 2017 | 2135 | | JSN 2135 Truven Commercial and Medicare Data Download |
Mar 17, 2017 | 2149 | | JSN 2149 J&J Q3 2015 Earnings Call Transcript Download |
Mar 17, 2017 | 2112 | | JSN 2112 Boehringer-Ingelheim-BTG Press Release ¿¿¿ ¿¿¿NEW TREATMENT FOR PROSTATE CANCER UNDER DEVELOPMENT,¿¿¿ dated May 22, 1996 Download |
Mar 17, 2017 | 2167 | | JSN 2167 June 4, 2013 Response to Office Action (from prosecution history of ¿¿¿438 patent) Download |
Mar 17, 2017 | 2124 | | JSN 2124 Deposition Transcript of Mark J. Ratain, M.D., taken by Patent Owner on January 23, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. Download |
Mar 17, 2017 | 2154 | | JSN 2154 Patent Owner Response in IPR2016-01332 Download |
Mar 17, 2017 | 42 | | Janssen Oncology, Inc.s Updated Exhibit List Download |
Mar 17, 2017 | 2160 | | JSN 2160 Deposition Transcript of Robert D. Stoner, taken by Patent Owner on February 10, 2017 Download |
Mar 17, 2017 | 2143 | | JSN 2143 J&J Q1 2014 Earnings Call Transcript Download |
Mar 17, 2017 | 2133 | | JSN 2133 Ryan, et al., ¿¿¿Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Download |
Mar 17, 2017 | 41 | | Motion to Seal Under 37 C.F.R. 42.14 and 42.54 Download |
Mar 17, 2017 | 2130 | | JSN 2130 Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Poster Download |
Mar 17, 2017 | 2152 | | JSN 2152 Declaration of Bindu Donovan Download |
Mar 17, 2017 | 2115 | | JSN 2115 Redacted Expert Report of Christopher Vellturo Download |
Mar 17, 2017 | 2157 | | JSN 2157 Sweeney, ¿¿¿ECOG 3805: CHAARTED ¿¿¿ ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer,¿¿¿ Download |
Mar 17, 2017 | 2164 | | JSN 2164 July 3, 2013 Notice of Allowance from prosecution history of
¿¿¿438 patent Download |
Mar 17, 2017 | 2134 | | JSN 2134 ZYTIGA Market Share data Download |
Mar 17, 2017 | 2132 | | JSN 2132 Order Granting Janssen¿¿¿s Motion to Set a Hearing and Correct Inventorship of the ¿¿¿438 Patent Download |
Mar 17, 2017 | 2125 | | JSN 2125 Deposition Transcript of Richard Dorin, M.D., taken by Patent Owner on January 19, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. Download |
Mar 22, 2017 | 44 | | Petitioner's Notice of Deposition of Christopher A. Vellturo, Ph.D. Download |
Mar 24, 2017 | 45 | | Petitioner's Objections to Patent Owner's Evidence Download |
Mar 24, 2017 | 48 | | Petitioner's Notice of Deposition of Christopher A. Vellturo, Ph.D. Download |
Mar 24, 2017 | 46 | | Petitioner's Notice of Deposition of Ian Judson, M.D. Download |
Mar 24, 2017 | 47 | | Petitioner's Notice of Deposition of Matthew Rettig, M.D. Download |
Mar 27, 2017 | 49 | | Petitioner's Notice of Deposition of Richard Auchus, M.D., Ph.D. Download |
Apr 3, 2017 | 50 | | Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Alyssa B. Monsen Download |
Apr 3, 2017 | 2169 | | JSN 2169 Declaration of Alyssa B. Monsen Download |
Apr 19, 2017 | 1088 | | Deposition Transcript of Ian Judson, M.D., Friday, April 7, 2017 Download |
Apr 19, 2017 | 1101 | | Mohler 2004 Download |
Apr 19, 2017 | 1117 | | Auerbauch U.S. Pat. Appl. Publ. No. 2015/0005268 Download |
Apr 19, 2017 | 1113 | | Storlie 1995 Download |
Apr 19, 2017 | 1085 | | Declaration of Matthew B. Rettig, M.D. (submitted in IPR2016-01332) Download |
Apr 19, 2017 | 1102 | | The Institute of Cancer Research, "Abiraterone: a story of scientific innovation and commercial partnership," Download |
Apr 19, 2017 | 1115 | | Deposition Transcript of Richard Auchus, M.D., Ph.D., Thursday, December 15, 2016 (IPR2016-00286) Download |
Apr 19, 2017 | 1105 | | Updated Curriculum Vitae for Paul A. Godley, MD, Ph.D., MPP Download |
Apr 19, 2017 | 1116 | | Cancer.org (ACS) Download |
Apr 19, 2017 | 1099 | | Deposition Transcript of Christopher A. Vellturo, Ph.D., Wednesday, April 5, 2017 Download |
Apr 19, 2017 | 1082 | | Montgomery 2016 Download |
Apr 19, 2017 | 1092 | | Attard 2012 Download |
Apr 19, 2017 | 1098 | | Updated Curriculum Vitae for Dr. Robert D. Stoner Download |
Apr 19, 2017 | 1106 | | Declaration of Ian McKeague, Ph.D Download |
Apr 19, 2017 | 1090 | | Auchus 2001 Download |
Apr 19, 2017 | 1120 | | Deposition Transcript of Christopher A. Vellturo, Ph.D., Tuesday, December 20, 2016 (IPR2016-00286) Download |
Apr 19, 2017 | 1097 | | Deposition Transcript of Matthew B. Rettig, M.D., Friday, March 31, 2017 Download |
Apr 19, 2017 | 1093 | | Akakura 2003 Download |
Apr 19, 2017 | 1108 | | DiMasi 2016 Download |
Apr 19, 2017 | 1114 | | David 2005 Download |
Apr 19, 2017 | 1083 | | Nishimura 2000 Download |
Apr 19, 2017 | 1107 | | Mestre-Ferrandiz 2012 Download |
Apr 19, 2017 | 1100 | | Cancer Research UK, "Our milestones: the birth of a new prostate cancer drug," Download |
Apr 19, 2017 | 1110 | | Zytiga¿¿ Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy Download |
Apr 19, 2017 | 1111 | | Dizdar 2015 Download |
Apr 19, 2017 | 1122 | | Second Declaration of Robert D. Stoner, Ph.D. (Redacted) Download |
Apr 19, 2017 | 1119 | | Cougar Biotechnology, Inc. Download |
Apr 19, 2017 | 1091 | | Auchus 2014 Download |
Apr 19, 2017 | 1121 | | Deposition Transcript of Richard J. Auchus, M.D., Ph.D., Monday, April 10, 2017 (Redacted) Download |
Apr 19, 2017 | 1096 | | Reid 2010 Download |
Apr 19, 2017 | 1086 | | Declaration of Marc B. Garnick, M.D. (submitted in IPR2016-01332) Download |
Apr 19, 2017 | 1095 | | Ryan 2010 Download |
Apr 19, 2017 | 1104 | | Second Declaration of Paul A. Godley, MD, Ph.D., MPP Download |
Apr 19, 2017 | 1109 | | NCT0205010 Download |
Apr 19, 2017 | 1118 | | Canger.gov (NIH NCI) Download |
Apr 19, 2017 | 1094 | | Attard 2016 Download |
Apr 19, 2017 | 1112 | | EMA ¿¿¿ Zytiga Product Information Download |
Apr 19, 2017 | 1084 | | Declaration of Matthew B. Rettig, M.D. (submitted in IPR2016-00286) Download |
Apr 19, 2017 | 1087 | | "BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology," Download |
Apr 19, 2017 | 51 | | Decision on Motion for Pro Hac Vice Admission of Alyssa B. Monsen Download |
Apr 19, 2017 | 54 | | Petitioner's Reply to Patent Owner Response Download |
Apr 19, 2017 | 55 | | Petitioner's Updated Mandatory Notices Download |
Apr 19, 2017 | 52 | | Petitioner's Motion to Seal Download |
Apr 19, 2017 | 53 | | Petitioner's Updated Exhibit List Download |
Apr 20, 2017 | 56 | | Patent Owner¿¿¿s Notice of Deposition of Robert D. Stoner, Ph.D. Download |
Apr 21, 2017 | 58 | | Petitioner's Motion to Withdraw Back-Up Counsel and Substitute New Back-Up Counsel Download |
Apr 21, 2017 | 57 | | Patent Owners Notice of Deposition of Paul A. Godley, M.D., Ph.D., M.P.P. Download |
Apr 26, 2017 | 59 | | Decision - Unopposed Motion to Withdraw - 37 CFR 42.10(e) Download |
Apr 26, 2017 | 60 | | Patent Owners Objections to Evidence Download |
May 3, 2017 | 61 | | Petitioner's Request for Oral Hearing Download |
May 5, 2017 | 64 | | Patent Owners Motion for Observation on Cross-Examination Download |
May 5, 2017 | 63 | | Patent Owners Motion to Exclude Evidence Pursuant to 37 C.F.R. 42.64c Download |
May 5, 2017 | 2187 | | JSN 2187 Download |
May 5, 2017 | 65 | | Janssen Oncology Inc.s Updated Exhibit List Download |
May 5, 2017 | 62 | | Patent Owner's Request for Oral Argument Download |
May 5, 2017 | 2183 | | JSN 2183 Download |
May 5, 2017 | 2184 | | JSN 2184 Download |
May 5, 2017 | 2185 | | JSN 2185 Download |
May 5, 2017 | 2186 | | JSN 2186 Download |
May 5, 2017 | 2177 | | JSN 2177 Download |
May 12, 2017 | 1129 | | Supplemental Declaration of Paul A. Godley, M.D., Ph.D., MPP Download |
May 12, 2017 | 1126 | | Replacement of WCK1090 Download |
May 12, 2017 | 1123 | | Supplemental Declaration of Declaration of Paul A. Godley, M.D., Ph.D., MPP Download |
May 12, 2017 | 1127 | | Replacement of WCK1112 Download |
May 12, 2017 | 1130 | | Supplemental Declaration of Robert D. Stoner, Ph.D. Download |
May 12, 2017 | 1124 | | Second Supplemental Declaration of Robert D. Stoner, Ph.D. Download |
May 12, 2017 | 1128 | | Replacement of WCK1128 Download |
May 12, 2017 | 1125 | | Declaration of Lestin L. Kenton Jr. Download |
May 12, 2017 | 1131 | | Supplemental to WCK1070 Download |
May 12, 2017 | 66 | | Petitioner's Opposition to Patent Owner's Motion to Exclude Evidence Download |
May 12, 2017 | 67 | | Petitioner's Updated Exhibit List Download |
May 12, 2017 | 68 | | Petitioner's Response to Patent Owner's Motion for Observations on Cross-Examination of Petitioner's Reply Witnesses Download |
May 15, 2017 | 69 | | ORDER TRIAL HEARING Download |
May 19, 2017 | 70 | | Patent Owners Reply in Support of Its Motion to Exclude Evidence Pursuant to 37 C.F.R 42.64(c) Download |
Jun 23, 2017 | 71 | | Record of Oral Hearing Download |
Jan 17, 2018 | 72 | | Final Written Decision Download |
Feb 16, 2018 | 73 | | Patent Owners Request for Rehearing Download |
Jul 23, 2018 | 74 | | Updated Mandatory Notices Download |
Sep 28, 2018 | 75 | | Panel Change Order Download |
Dec 3, 2018 | 76 | | Decision Denying Patent Owner's Request for Rehearing Download |
Dec 19, 2018 | 77 | | Patent Owner's Notice of Appeal Download |
Jul 16, 2019 | 78 | | Patent Owners Motion to Expunge Under 37 C.F.R. 42.56 Download |
Aug 29, 2019 | 79 | | Granting-In-Part Patent Owner's Motion to Expunge
37 C.F.R. secs. 42.14, 42.56 Download |